Home » Stocks » RUBY

Rubius Therapeutics, Inc. (RUBY)

Stock Price: $4.65 USD 0.09 (1.97%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Pre-market: $4.96 +0.31 (6.67%) Oct 28, 8:07 AM

Stock Price Chart

Key Info

Market Cap 375.57M
Revenue (ttm) n/a
Net Income (ttm) -177.83M
Shares Out 80.77M
EPS (ttm) -2.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $4.65
Previous Close $4.56
Change ($) 0.09
Change (%) 1.97%
Day's Open 4.57
Day's Range 4.50 - 4.80
Day's Volume 186,157
52-Week Range 3.35 - 14.44

More Stats

Market Cap 375.57M
Enterprise Value 256.20M
Earnings Date (est) Nov 12, 2020
Ex-Dividend Date n/a
Shares Outstanding 80.77M
Float 32.40M
EPS (basic) -2.22
EPS (diluted) -2.23
FCF / Share -1.91
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8.36M
Short Ratio 36.85
Short % of Float 25.79%
Beta 1.98
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.80
Revenue n/a
Operating Income -180.46M
Net Income -177.83M
Free Cash Flow -153.49M
Net Cash 119.37M
Net Cash / Share 1.48
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -28.83%
ROE -64.77%
ROIC -52.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 3
Overweight 0
Hold 3
Underweight 1
Sell 0

Analyst Consensus: Overweight

Price Target

(102.80% upside)
Current: $4.65
Target: 9.43
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-170-91.66-43.26-10.85
Net Income-163-89.20-43.85-11.02
Shares Outstanding78.6939.298.027.20
Earnings Per Share-2.08-2.27-5.55-1.63
Operating Cash Flow-110-58.34-21.94-9.50
Capital Expenditures-40.66-14.95-2.25-0.44
Free Cash Flow-151-73.29-24.19-9.95
Cash & Equivalents2854061057.07
Total Debt97.0065.795.443.92
Net Cash / Debt18834199.133.14
Book Value274393-43.69-17.12
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Rubius Therapeutics, Inc.
Country United States
Employees 199
CEO Pablo J. Cagnoni

Stock Information

Ticker Symbol RUBY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RUBY
IPO Date July 18, 2018


Rubius Therapeutics focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.